ORLANDO, Fla. — In June, Dr. Samit Hirawat was appointed chief medical officer of Bristol-Myers Squibb, where he is in charge of the pharma’s late-stage drug development across all therapeutics areas. He joined Bristol after spending 12 years at Novartis. Hirawat’s new job got a lot bigger and more involved last month when Bristol’s merger with Celgene was completed.
STAT interviewed Hirawat here at the annual meeting of the American Society of Hematology, where he talked about Bristol’s commitment to developing CAR-T therapies, how he’s managing the integration of the two pipelines, and whether he’s prepared to say no when data go bad. This interview has been condensed and lightly edited.
It’s a little disorienting to be at ASH and not see Celgene here — and I mean as a standalone company. This is also your first ASH running global drug development for the combined companies under the Bristol banner. What’s that like for you?
About the Author Reprints
